Dasatinib

Description

Dasatinib is used for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML), a type of blood cancer that occurs due to a chromosome abnormality. It is also used for the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), a type of white blood cell cancer where the bone marrow produces cancerous and immature lymphoblasts in large quantities. This medicine is not recommended for patients below 1 year of age.

Side effects

Major & minor side effects for Dasatinib

  • Body aches or Pain
  • Burning, numbness, tingling in the arms and feet
  • Chest pain
  • Chills
  • Cough
  • Dizziness
  • Headache
  • Weight gain
  • Fever
  • Irritation of throat
  • Ulcers or white spots in the mouth
  • Nausea
  • Irregular breathing
  • Increased sweating

Uses of Dasatinib

What is it prescribed for?

  • Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML)
  • Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL)
Read More
Concerns

Commonly asked questions

  • Onset of action
    The amount of time taken by this medicine to show its effect is subject to vary based on the intended use.
  • Duration of effect
    The amount of time for which this medicine remains effective in the body is subject to vary based on the intended use and duration of use.
  • Safe with alcohol?
    Interaction with alcohol is unknown. It is advisable to consult your doctor before consumption.
  • Is it habit forming?
    No habit-forming tendencies were reported.
  • Usage in pregnancy?
    This medicine is not recommended for use in pregnant women unless absolutely necessary. The risks and benefits should be discussed with the doctor before taking this medicine.
  • Usage while breast-feeding?
    This medicine is not recommended for use in breastfeeding women unless absolutely necessary. The risks and benefits should be discussed with the doctor before taking this medicine. Your doctor may advise you to discontinue breastfeeding or to discontinue the medicine based on your clinical condition.

Allergy

This medicine is not recommended for use in patients with a known allergy to Dasatinib or any other inactive ingredients present along with it.
Warnings for special population

Pregnancy

This medicine is not recommended for use in pregnant women unless absolutely necessary. The risks and benefits should be discussed with the doctor before taking this medicine.

Breast-feeding

This medicine is not recommended for use in breastfeeding women unless absolutely necessary. The risks and benefits should be discussed with the doctor before taking this medicine. Your doctor may advise you to discontinue breastfeeding or to discontinue the medicine based on your clinical condition.
General warnings

Gastrointestinal disorders

This medicine should be used with caution in patients having a pre-existing disorder of the stomach or the intestine due to the increased risk of worsening of the patient's condition. Replacement with a suitable alternative may be necessary based on the clinical condition.

Driving or Operating machinery

Use of this medicine may cause dizziness and blurring of vision. Hence, it is advised that you do not perform any activities that require high mental alertness such as driving a vehicle or operating heavy machinery during treatment with this medicine.

Bonemarrow suppression

This medicine should be used with caution in patients having conditions like thrombocytopenia, agranulocytosis, anemia, or bone marrow suppression due to the increased risk of worsening of the patient's condition. A complete blood count should be performed before initiating treatment with this medicine. Close monitoring of blood counts is recommended during treatment with this medicine. Appropriate dose adjustments or replacement with a suitable alternative may be required based on the clinical condition.

Internal bleeding or hemorrhage

This medicine should be used with caution due to the increased risk of internal bleeding or hemorrhages. Any symptoms such as unusual bleeding or bruising, black or tarry stools, vomiting up blood, etc. should be reported to the doctor on priority. Appropriate dose adjustments or replacement with a suitable alternative may be required based on the clinical condition.

Risk of infections

Use of this medicine may weaken the immune system and may make you more vulnerable to infections. It is advised that you avoid coming in contact with people suffering from an infection while taking this medicine.

Pulmonary arterial hypertension (PAH)

This medicine should be used with caution in patients Pulmonary arterial hypertension (PAH) due to the increased risk of worsening of the patient's condition. Close monitoring of blood pressure levels is recommended during treatment with this medicine. Appropriate dose adjustments or replacement with a suitable alternative may be required based on the clinical condition.

QT interval prolongation

This medicine should be used with extreme caution in patients who have or may develop prolongation of QT interval due to the increased risk of worsening of the patient's condition. Close monitoring of clinical condition, appropriate dose adjustments or replacement with a suitable alternative may be required based on the clinical condition.

Missed Dose

Take the missed dose as soon as you remember. If it is almost the time for your next dose, skip the missed dose. Do not double your dose to make up for the missed dose.

Overdose

Seek emergency medical treatment or contact the doctor in case of an overdose.
All drugs interact differently for person to person. You should check all the possible interactions with your doctor before starting any medicine.
Interaction with Alcohol

Description

Interaction with alcohol is unknown. It is advisable to consult your doctor before consumption.

Instructions

Interaction with alcohol is unknown. It is advisable to consult your doctor before consumption.
Interaction with Medicine

BCG vaccine

Adalimumab

Alteplase

Dabigatran

Cisapride

Diclofenac

Disease interactions

Heart and blood vessel disorder

This medicine should be used with caution in patients having a disease of the heart or the blood vessels due to the increased risk of worsening of the patient's condition. Close monitoring of heart function is recommended for such patients. Appropriate corrective measures, dose adjustments, or replacement with a suitable alternative may be necessary based on the clinical condition.

Fluid Retention and edema

This medicine should be used with caution in patients having fluid retention disorders due to the increased risk of worsening of the patient's condition. Appropriate corrective measures, dose adjustments, or replacement with a suitable alternative may be necessary based on the clinical condition.

Hepatic impairment

This medicine should be used with caution in patients suffering from liver diseases due to the increased risk of worsening of the patient's condition. Close monitoring of liver function is necessary while receiving this medicine. Appropriate dose adjustments or replacement with a suitable alternative may be required in some cases based on the clinical condition of the patient.
Food interactions
Consumption of grapefruit or grapefruit juice is not recommended during treatment with this medicine due to the increased risk of severe adverse effects.
Lab interactions
Information not available.
Take this medicine exactly as prescribed by the doctor. Do not take in larger or smaller amounts than advised/prescribed. Consult the doctor if you experience any undesirable side effects. Ensure that the course of treatment is completed. Do not stop the use of this medicine without consulting your doctor.
Miscelleneous

Can be taken with or without food, as advised by your doctor

To be taken as instructed by doctor

May cause sleepiness

How it works
This medicine works by inhibiting the actions of certain abnormal proteins that cause the cancer cells to multiply. This helps in stopping the growth and spread of cancer.
Legal Status

Approved

Approved

Approved

Approved

Classification

Category

BCR-ABL tyrosine kinase inhibitors

Schedule

Schedule H

[Internet]. 2018 [cited 5 December 2018]. Available from:

https://www.medsafe.govt.nz/Consumers/CMI/s/Sprycel.pdf

[Internet]. Accessdata.fda.gov. 2018 [cited 5 December 2018]. Available from:

https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021986s004lbl.pdf

Dasatinib: MedlinePlus Drug Information [Internet]. Medlineplus.gov. 2018 [cited 5 December 2018]. Available from:

https://medlineplus.gov/druginfo/meds/a607063.html

[Internet]. Medicines.org.uk. 2018 [cited 5 December 2018]. Available from:

https://www.medicines.org.uk/emc/files/pil.7745.pdf

[Internet]. Packageinserts.bms.com. 2018 [cited 5 December 2018]. Available from:

https://packageinserts.bms.com/ppi/ppi_sprycel.pdf

Dasatinib - DrugBank [Internet]. Drugbank.ca. 2018 [cited 5 December 2018]. Available from:

https://www.drugbank.ca/drugs/DB01254

How will this medicine affect me?

Consult top doctors online and get an answer now
Chat now

Looking for a doctor?

Book an appointment with the top doctors near you
Book now
Something doesn’t feel right?
Report an error

Information on this page was last updated on 5 Feb 2019

Disclaimer

We’ve made all possible efforts to ensure that the information provided here is accurate, up-to-date and complete, however, it should not be treated as a substitute for professional medical advice, diagnosis or treatment. Practo only provides reference source for common information on medicines and does not guarantee its accuracy or exhaustiveness. The absence of a warning for any drug or combination thereof, should not be assumed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Practo does not assume any responsibility for any aspect of healthcare administered with the aid of information provided above. If you have any doubts about your medication then we strongly recommend that you consult with your doctor, nurse or healthcare provider. See detailed T&C here.